Plasma Exchange in Patients of Acute on Chronic Liver Failure: An Observational Study in Bangladesh
Abdullah Al Mukit, Md. Abdur Rahim, Seikh Mohammad Noor-E-Alam, Dulal Chandra Das, Ahmed Lutful Moben, Faiz Ahmad Khondaker, Md. Ashraful Alam, Rokshana Begum, Mohammad Ekramul Haque, Md. Atikul Islam, Ayub Al Mamun, Sheikh Mohammad Fazle Akbar
Acute on chronic liver failure, Parameters of liver diseases, Plasma exchange, Survival
Citation Information :
Al Mukit A, Rahim MA, Noor-E-Alam SM, Das DC, Moben AL, Khondaker FA, Alam MA, Begum R, Haque ME, Islam MA, Al Mamun A, Akbar SM. Plasma Exchange in Patients of Acute on Chronic Liver Failure: An Observational Study in Bangladesh. Euroasian J Hepatogastroenterol 2022; 12 (1):1-5.
Background: Therapeutic plasma exchange (PLEX) removes toxins and different mediators from plasma in patients with acute-on-chronic liver failure (ACLF).
Aim: To observe the safety and outcome of PLEX in ACLF patients in Bangladesh.
Materials and methods: Twenty-eight patients with ACLF attending Bangabandhu Sheikh Mujib Medical University from September 2020 to May 2021 were enrolled in the study. The patients were given different treatment modalities and followed up for 3 months or up to death. The patients were divided into two groups, each containing 14 patients of ACLF. One group of 14 patients received standard medical therapy (SMT) for ACLF and the second group of 14 patients received SMT plus PLEX.
Results: At 90 days, a total of 13 patients (46.43%) survived, of them 8 (57.1%) belonged to PLEX group and 5 (35.7%) were from SMT group. Serum bilirubin and ALT declined significantly after 7 and 30 days but not after 90 days in PLEX group in comparison to SMT group (p <0.05) but other biochemical parameters were not significantly different (p >0.05) between these two groups. Significant (p <0.05) improvement of MELD, MELD-Na, and AARC scores was observed in each group from baseline to subsequent first, second, and third follow-up but no significant (p >0.05) difference was observed in between two groups. Binary logistic regression analysis found that bilirubin, MELD score, MELD-Na score, and AARC score were predictors of mortality.
Conclusion: The study presented here has shown that PLEX is safe in Bangladeshi in ACLF patients, but its efficacy remains to be checked in large-scale randomized trial or in combination therapy with other procedures in ACLF patients.
Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure’: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3(1):269–282. DOI: 10.1007/s12072-008-9106-x.
Wendon JP, Cordoba J, Dhawan A, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017;66(5):1047–1081. DOI: 10.1016/j.jhep.2016.12.003.
Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144(7): 1426–1437. DOI: 10.1053/j.gastro.2013.02.042.
Vizzutti F, Arena U, Laffi G, et al. Acute on chronic liver failure: from pathophysiology to clinical management. Trends Anaesth Crit Care 2013;3:122–129. DOI: 10.1016/j.tacc.2013.01.006.
Chen JJ, Huang JR, Yang Q, et al. Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China. Hepatobiliary Pancreat Dis Int 2016;15(3):275–281. DOI: 10.1016/s1499-3872(16)60084-x.
Chen YY, Li H, Xu BY, et al. Plasma exchange-based non-bioartificial liver support system improves the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure: a multicenter prospective cohort study. Front Med 2021;8;Article 779744. DOI: 10.3389/fmed.2021.779744.
Stahl K, Busch M, Fuge J, et al. Therapeutic plasma exchange in acute on chronic liver failure. J Clin Apher 2020;35(4):316–327. DOI: 10.1002/jca.21799.
Deshpande A, Kumbar S, Patil S, et al. Plasma exchange therapy in patients with ACLF, experience from a tertiary care center. J Clin Exp Hepatol 2018;8(1). DOI: 10.1016/j.jceh.2018.06.276.
Al-Mahtab M, Akbar SM, Garg H. Influence of variceal bleeding on natural history of ACLF and management options. Hepatol Int 2016;10(3):436–439. DOI: 10.1007/s12072-015-9677-2.
Mahtab MA, Rahman S, Khan M, et al. Hepatitis E virus is a leading cause of acute-on-chronic liver disease: experience from a tertiary centre in Bangladesh. Hepatobiliary Pancreat Dis Int 2009;8(1):50–52. PMID: 19208515.
Haque MN, Al-Mahtab M, Das DC, et al. Effect of granulocyte colony-stimulating factor and erythropoietin on patients with acute-on-chronic liver failure. Euro J Hepatogastroenterol 2020;10(2):64–67. DOI: 10.5005/jp-journals-10018-1330.
Saha BK, Mahtab MA, Akbar SMF, et al. Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure: increased survival and containment of liver damage. APASL ACLF working party. Hepatol Int 2017;11(6):540–546. DOI: 10.1007/s12072-017-9814-1.
Xu W, Li Y, Wang L, et al. Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial. BMJ Open 2021 Dec 14;11(12):e047690. DOI: 10.1136/bmjopen-2020-047690.
Ocskay K, Kanjo A, Gede N, et al. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis. Ann Intensive Care 2021;11(1):10. DOI: 10.1186/s13613-020-00795-0.